ABPR yields 2000000.00% · ABBV yields 3.06%● Live data
📍 ABPR pulled ahead of the other in Year 1
Combined, ABPR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ABPR + ABBV for your $10,000?
Airborne Security & Protective Services, Inc. operates as a security service company in the United States. It offers personnel security services, including event security, fire watch or incident watch, investigations, loss prevention, security consultants, interior and exterior escort services, off duty LEO, motor escort, and K9, as well as concierge, front desk, and doorman services. The company also provides unarmed officers, who observe, report, and maintain access control; unarmed officer with tasers, batons, and handcuffs used in medium risk facilities; armed officers with firearms, batons, and handcuffs used in high risk facilities; and executive protection specialists. In addition, it offers security system services, such as access control, anti-terrorism standards and training, drug and alcohol detection, evacuation planning, law enforcement communication, inventory control, ID/badge systems, incident management, post-order/safety, security plan development, vehicle bomb search techniques, perimeter protection, alarm monitoring, CCTV installation and monitoring, client training, ATM servicing, high Value/risk transport, and secure transactions, as well as CPR, first aid, and AED services. The company was formerly known as Quality Restaurant Ventures, Inc. and changed its name to Airborne Security & Protective Services, Inc. in April 2010. Airborne Security & Protective Services, Inc. is headquartered in North Miami Beach, Florida.
Full ABPR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.